


CLAIMS

1-35. (canceled)

Please add the following new claims:

36. (new) A compound of formula I



each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, or halogen;

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen;

R<sup>3</sup> is C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, or unsubstituted or substituted carbamoyl;

R<sup>4</sup> is hydrogen;

R<sup>5</sup> is chloro or bromo;

R<sup>6</sup> is hydrogen;

each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocycll comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

$R^8$  is  $C_5\text{-}C_{10}\text{aryl}$ ; unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S;  $C_5\text{-}C_{10}\text{aryloxy}$ ; unsubstituted or substituted heterocyclyloxy; or unsubstituted or substituted heterocyclyl $C_1\text{-}C_8\text{alkoxy}$ ; and  $R^{10}$  is  $C_1\text{-}C_8\text{alkyl}$ , halo $C_1\text{-}C_8\text{alkyl}$ ,  $C_1\text{-}C_8\text{alkoxy}$ , unsubstituted or substituted heterocyclyl $C_1\text{-}C_8\text{alkoxy}$ , unsubstituted or substituted amino, or halogen; and

A is C;

or salts thereof.

37. (new) The compound of claim 36, wherein each of  $R^0$ ,  $R^1$  or  $R^2$  is hydrogen.

38. (new) The compound of claim 36, wherein  $R^3$  is  $C_1\text{-}C_8\text{alkylsulfonyl}$ ,  $C_5\text{-}C_{10}\text{arylsulfonyl}$  or unsubstituted or substituted carbamoyl.

39. (new) The compound of claim 36, wherein  $R^3$  is  $C_1\text{-}C_8\text{alkylsulfonyl}$ .

40. (new) The compound of claim 36, wherein  $R^3$  is  $C_5\text{-}C_{10}\text{arylsulfonyl}$ .

41. (new) The compound of claim 36, wherein  $R^3$  is unsubstituted or substituted carbamoyl.

42. (new) The compound of claim 36, wherein  $R^8$  is piperidino, piperazino, N-methylpiperazino, morpholino, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy or 3-(N-methylpiperazino)-propoxy.


43. (new) The compound of claim 36, wherein  $R^8$  is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.

44. (new) The compound of claim 36, wherein  $R^0$ ,  $R^1$  or  $R^2$  is hydrogen;  $R^3$  is  $C_1\text{-}C_8\text{alkylsulfonyl}$ ; and  $R^8$  is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.

45. (new) The compound of claim 44, wherein  $R^8$  is piperidino, piperazino, N-methylpiperazino or morpholino.

46. (new) The compound of claim 36, wherein said compound is selected from the group of compounds with the following names or formulae:






2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide;










a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound No.	Rx
7-1	
7-2	
7-3	

7-4	
7-5	
7-7	
7-8	
7-9	


7-10	
7-11	
7-12	
7-13	
7-14	

7-17	
7-18	
7-20	
7-21	
7-25	







a compound of the formula  
given in the following table:



Compound	R <sub>x</sub>
8-2	<p>The chemical structure of compound 8-2 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group.</p>





a compound of the formula  
given in the following table:



Compound	R <sub>x</sub>
9-1	<p>The chemical structure of compound 9-1 is a piperazine ring substituted at the 4-position with a 4-methoxyphenyl group.</p>


9-2	
9-3	
9-4	
9-5	







a compound of the formula  
given in the following table:

Compound	Rx
10-1	
10-2	




a compound of the formula  , wherein Rx has one of the meanings given in the following table:

Compound	Rx
11-1	
11-2	
11-4	 ;




a compound of the formula , wherein Ry has one of the meanings given in the following table:

Compound	Ry
14-1	
14-2	
14-3	
14-5	
14-6	




a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
15-1	
15-2	
15-3	;








a compound of the formula , wherein Rx has one of the meanings given in the following table:





Compound	Rx
18-1	 ;







a compound of the formula , wherein Rx has one of the meanings given in the following table:





Compound	Rx
26-1	
26-2	


26-3	
26-4	
26-5	
26-6	
26-7	

26-8	
26-9	
26-10	
26-11	

26-12	
26-13	
26-14	
26-18	






26-21	
26-22	
26-23	
26-24	
26-25	




26-26	
26-27	
26-28	
26-29	





a compound of the formula  
given in the following table:






Compound	Rx
----------	----


27-1	
27-2	
27-3	
27-4	
27-5	





27-6	
27-8	
27-9	 ;







a compound of the formula  
 , wherein Rx has one of the meanings  
given in the following table:


Compound	Rx
28-1	
28-2	
28-3	
28-4	
28-5	




28-11	
28-12	
28-13	
28-14	

28-15	
28-16	
28-17	
28-18	
28-19	


28-20	
28-21	
28-22	
28-23	






a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
29-1	
29-2	
29-3	




a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
31-2	




a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
32-1	
32-2	




a compound of the formula , wherein Ry has one of the meanings given in the following table:

Compound	Ry
34-1	
34-3	
34-4	
34-6	; and




a compound of the formula , wherein Rx has one of the meanings given in the following table:

Compound	Rx
35-1	 ;


or a pharmaceutically acceptable salt thereof.

47. (new) The compound of claim 36, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N<sup>2</sup>-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N<sup>4</sup>-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

48. (new) A process for the production of a compound of formula I according to claim 36, comprising reacting a compound of formula II



wherein R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are as defined in claim 36, and Y is a leaving group, with a compound of formula III



wherein A, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are as defined in claim 36;  
and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 36, into another compound of formula I as defined in claim 36;

and recovering the resulting compound of formula I in free form or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

49. (new) A pharmaceutical composition comprising a compound according to claim 36, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

50. (new) A combination comprising a therapeutically effective amount of a compound according to claim 36 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.

51. (new) A method for the treatment of breast tumors in a subject in need thereof which comprises administering an effective amount of a compound according to claim 36 or a pharmaceutical composition comprising same.

52. (new) The method of claim 51, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N<sup>2</sup>-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N<sup>4</sup>-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.